A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Hoffmann, Markus, Kleine-Weber, Hannah, Pöhlmann, Stefan·2020·Molecular Cell
DOI 10.1016/j.molcel.2020.04.022

Cited by (1,004)

Items 101–200 of 1,004

  1. SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development
    Nicholas Murgolo, Alex G. Therien, Bonnie J. Howell, Daniel J. Klein, Kenneth A. Koeplinger, Linda A. Lieberman, Gregory C. Adam, Jessica A. Flynn, Philip M. McKenna, Gokul Swaminathan et al. · 2021 · PLoS Pathogens
  2. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
    Renuka Raman, Krishna J. Patel, Kishu Ranjan · 2021 · Biomolecules
  3. I mmunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People
    Anna Julia Pietrobon, Franciane Mouradian Emidio Teixeira, Maria Notomi Sato · 2020 · Frontiers in Immunology
  4. Proteolytic activation of SARS‐CoV‐2 spike protein
    Makoto Takeda · 2021 · Microbiology and Immunology
  5. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity
    Rachid Essalmani, Jaspreet Jain, Delia Susan‐Resiga, Ursula Andréo, Alexandra Evagelidis, Rabeb Mouna Derbali, David N. Huynh, Frédéric Dallaire, Mélanie Laporte, Adrien Delpal et al. · 2022 · Journal of Virology
  6. A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19
    Zhou, Yadi, Hou, Yuan, Shen, Jiayu, Mehra, Reena, Kallianpur, Asha, Culver, Daniel A., Gack, Michaela U., Farha, Samar, Zein, Joe, Comhair, Suzy et al. · 2020 · PLoS Biology
  7. Peptide and peptide-based inhibitors of SARS-CoV-2 entry
    Desirée Schütz, Yasser B. Ruiz‐Blanco, Jan Münch, Frank Kirchhoff, Elsa Sánchez‐García, Janis A. Müller · 2020 · Advanced Drug Delivery Reviews
  8. SARS-CoV-2 variants with mutations at the S1/S2 cleavage site are generated in vitro during propagation in TMPRSS2-deficient cells
    Michihito Sasaki, Kentaro Uemura, Akihiko Sato, Shinsuke Toba, Takao Sanaki, Katsumi Maenaka, William W. Hall, Yasuko Orba, Hirofumi Sawa · 2021 · PLoS Pathogens
  9. SARS‐CoV‐2 Alpha, Beta, and Delta variants display enhanced Spike‐mediated syncytia formation
    Maaran Michael Rajah, Mathieu Hubert, Elodie Bishop, Nell Saunders, Rémy Robinot, Ludivine Grzelak, Delphine Planas, Jérémy Dufloo, Stacy Gellenoncourt, Alice Bongers et al. · 2021 · The EMBO Journal
  10. Predicting the mutational drivers of future SARS-CoV-2 variants of concern
    M. Cyrus Maher, István Bartha, Steven Weaver, Julia di Iulio, Elena Ferri, Leah B. Soriaga, Florian A. Lempp, Brian Hie, Bryan D. Bryson, Bonnie Berger et al. · 2022 · Science Translational Medicine
  11. The role of high cholesterol in SARS-CoV-2 infectivity
    Hao Wang, Zixuan Yuan, Mahmud Arif Pavel, Sonia Mediouni Jablonski, Joseph Anthony Jablonski, Robert J. Hobson, Susana T. Valente, Chakravarthy B. Reddy, Scott B. Hansen · 2023 · Journal of Biological Chemistry
  12. The Mechanism and Consequences of SARS-CoV-2 Spike-Mediated Fusion and Syncytia Formation
    Maaran Michael Rajah, Annie Bernier, Julian Buchrieser, Olivier Schwartz · 2021 · Journal of Molecular Biology
  13. T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis
    Bahire Kalfaoglu, José Almeida‐Santos, Chanidapa Adele Tye, Yorifumi Satou, Masahiro Ono · 2020 · Frontiers in Immunology
  14. SARS-CoV-2 spike protein binds to bacterial lipopolysaccharide and boosts proinflammatory activity
    Ganna Petruk, Manoj Puthia, Jitka Petrlová, Firdaus Samsudin, Ann‐Charlotte Strömdahl, Samuel Cerps, Lena Uller, Sven Kjellström, Peter John Bond, Artur Schmidtchen · 2020 · Journal of Molecular Cell Biology
  15. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV‑2 in Mice
    Abigail E. Powell, Kaiming Zhang, Mrinmoy Sanyal, Shaogeng Tang, Payton A. B. Weidenbacher, Shanshan Li, Tho D. Pham, John E. Pak, Wah Chiu, Peter S. Kim · 2021 · ACS Central Science
  16. Exploring the Natural Origins of SARS-CoV-2 in the Light of Recombination
    Spyros Lytras, Joseph Hughes, Darren Patrick Martin, Phillip Swanepoel, Arné de Klerk, Rentia Lourens, Sergei L. Kosakovsky Pond, Wei Xia, Xiaowei Jiang, David L. Robertson · 2022 · Genome Biology and Evolution
  17. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera
    A. Kuzmina, Y. Khalaila, O. Voloshin, A. Keren-Naus, Liora Boehm-Cohen, Y. Raviv, Y. Shemer-Avni, Elli Rosenberg, R. Taube · 2021 · Cell Host and Microbe
  18. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts
    Xiaofeng Zhai, Jiumeng Sun, Ziqing Yan, Jie Zhang, Jin Zhao, Zongzheng Zhao, Qi Gao, Wan-Ting He, Michael Veit, Shuo Su · 2020 · Journal of Virology
  19. Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission
    Alba Escalera, Ana Silvia Gonzalez-Reiche, Sadaf Aslam, Ignacio Mena, Manon Laporte, Rebecca L. Pearl, Andrea Fossati, Raveen Rathnasinghe, Hala Alshammary, Adriana van de Guchte et al. · 2022 · Cell Host & Microbe
  20. How the coronavirus infects cells — and why Delta is so dangerous
    Megan Scudellari · 2021 · Nature
  21. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
    Rauch, Susanne, Roth, Nicole, Schwendt, Kim, Fotin-Mleczek, Mariola, Mueller, Stefan O., Petsch, Benjamin · 2021 · npj Vaccines
  22. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2
    Xuesen Zhao, Danying Chen, Robert Szabla, Mei Zheng, Guoli Li, Pengcheng Du, Shuangli Zheng, Xinglin Li, Chuan Song, Rui Li et al. · 2020 · Journal of Virology
  23. Cell entry by SARS-CoV-2
    Ruchao Peng, Lian-Ao Wu, Qingling Wang, Jianxun Qi, George F. Gao · 2021 · Trends in Biochemical Sciences
  24. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
    Jun Siong Low, Josipa Jerak, M. Alejandra Tortorici, Matthew McCallum, Dora Pinto, Antonino Cassotta, Mathilde Foglierini, Federico Mele, Rana Abdelnabi, Birgit Weynand et al. · 2022 · Science
  25. The sequence at Spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV
    Mihkel Örd, Ilona Faustova, Mart Loog · 2020 · Scientific Reports
  26. The structural basis of accelerated host cell entry by SARS‐CoV‐2†
    Murat Seyran, Kazuo Takayama, Vladimir Nikolaevich Uversky, Kenneth H. Lundstrom, Giorgio Palù, Samendra P. Sherchan, Diksha Attrish, Nima Rezaei, Alaa A. A. Aljabali, Shinjini Ghosh et al. · 2020 · FEBS Journal
  27. Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
    John E. Bowen, Amin Addetia, Ha V. Dang, Cameron Stewart, Jack T Brown, William K. Sharkey, Kaitlin R. Sprouse, Alexandra C. Walls, Ignacio G. Mazzitelli, Jennifer K. Logue et al. · 2022 · Science
  28. SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2
    Lu Qiao, Jia Liu, Shuai Zhao, María Florencia Gómez Castro, Maudry Laurent-Rolle, Jianbo Dong, Xiaojuan Ran, Payal Damani‐Yokota, Hongzhen Tang, Triantafyllia R. Karakousi et al. · 2021 · Immunity
  29. Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
    Sindhu Ramesh, Manoj Govindarajulu, Rachel S. Parise, Logan T. Neel, Tharanath Shankar, Shriya Patel, Payton Lowery, Forrest Smith, Muralikrishnan Dhanasekaran, Timothy Moore · 2021 · Vaccines
  30. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection
    Pranesh Padmanabhan, Rajat Desikan, Narendra M. Dixit · 2020 · PLoS Computational Biology
  31. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
    Anna Z. Mykytyn, Tim I. Breugem, Samra Riesebosch, Debby Schipper, Petra B. van den Doel, Robbert J. Rottier, Mart Matthias Lamers, Bart L. Haagmans · 2021 · eLife
  32. Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
    Daniele Focosi, Fabrizio Maggi · 2021 · Reviews in Medical Virology
  33. The role of O-glycosylation in human disease
    Ana Magalhães, Henrique O. Duarte, Celso Albuquerque Reis · 2021 · Molecular Aspects of Medicine
  34. SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans
    Nchioua, Rayhane, Kmiec, Dorota, Müller, Janis A., Conzelmann, Carina, Groß, Rüdiger, Swanson, Chad M., Neil, Stuart J. D., Stenger, Steffen, Sauter, Daniel, Münch, Jan et al. · 2020 · mBio
  35. Evolutionary trajectory of SARS-CoV-2 and emerging variants
    Jalen Singh, Pranav Pandit, Andrew G. McArthur, Arinjay Banerjee, Karen Louise Mossman · 2021 · Virology Journal
  36. Antibody-mediated neutralization of SARS-CoV-2
    Henning Gruell, Kanika Vanshylla, Timm Weber, Christopher O. Barnes, Christoph Kreer, Florian Klein · 2022 · Immunity
  37. Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
    Tsai, Shang Jui, Atai, Nadia A., Cacciottolo, Mafalda, Nice, Justin, Salehi, Arjang, Guo, Chenxu, Sedgwick, Alanna, Kanagavelu, Saravana, Gould, Stephen J. · 2021 · Journal of Biological Chemistry
  38. Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics
    Andreas Ritter, Nina‐Naomi Kreis, Frank Louwen, Juping Yuan · 2020 · International Journal of Molecular Sciences
  39. Host and viral determinants for efficient SARS-CoV-2 infection of the human lung
    Hin Chu, Bingjie Hu, Xiner Huang, Yue Chai, Dongyan Zhou, Yixin Wang, Huiping Shuai, Dong Yang, Yuxin Hou, Xi Zhang et al. · 2021 · Nature Communications
  40. Virus-Mediated Cell-Cell Fusion
    Héloïse Leroy, Mingyu Han, Marie Woottum, Lucie Bracq, Jérôme Bouchet, Maorong Xie, Serge Bénichou · 2020 · International Journal of Molecular Sciences
  41. Two Years into the COVID-19 Pandemic: Lessons Learned
    Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Renata Pessôa Germano Mendes, Klarissa Miranda Guarines, Caroline Targino Alves da Silva, Poliana Gomes da Silva, Jurandy Júnior Ferraz de Magalhães, Justin R. J. Vigar, Abelardo Silva‐Júnior, Alain Kohl et al. · 2022 · ACS Infectious Diseases
  42. SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients
    Marjorie Cornejo Pontelli, Ítalo A. Castro, Ronaldo Bragança Martins Júnior, Leonardo La Serra, Flavio Protasio Veras, Daniele C. Nascimento, Camila Meirelles Souza Silva, Ricardo de Souza Cardoso, Roberta Rosales, Rogério Gomes et al. · 2022 · Journal of Molecular Cell Biology
  43. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
    Cong Sun, Chu Xie, Guo‐Long Bu, Lan‐Yi Zhong, Mu‐Sheng Zeng · 2022 · Signal Transduction and Targeted Therapy
  44. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator
    Jingwei Bian, Zijian Li · 2020 · Acta Pharmaceutica Sinica B
  45. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK
    Verity Hill, Louis du Plessis, Thomas P. Peacock, Dinesh Aggarwal, Rachel Colquhoun, Alessandro M. Carabelli, Nicholas A.F. Ellaby, Eileen Gallagher, Natalie Groves, Ben Jackson et al. · 2022 · Virus Evolution
  46. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
    McCallum, Matthew, Marco, Anna De, Lempp, Florian, Tortorici, M. Alejandra, Pinto, Dora, Walls, Alexandra C., Beltramello, Martina, Chen, Alex, Liu, Zhuoming, Zatta, Fabrizia et al. · 2021
  47. SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients
    Klimstra, William B., Tilston-Lunel, Natasha L., Nambulli, Sham, Boslett, James, McMillen, Cynthia M., Gilliland, Theron, Dunn, Matthew D., Sun, Chengun, Wheeler, Sarah E., Wells, Alan et al. · 2020 · Journal of General Virology
  48. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy
    Ying Wang, Chen Yang, Yutong Song, John Robert Coleman, Marcin Stawowczyk, Juliana Tafrova, Sybil A. Tasker, David A. Boltz, Robert Baker, Liliana Garcia et al. · 2021 · Proceedings of the National Academy of Sciences
  49. Furin cleavage of the SARS-CoV-2 spike is modulated by O -glycosylation
    Liping Zhang, Matthew D. Mann, Zulfeqhar Ali Syed, Hayley M. Reynolds, E Tian, Nadine L. Samara, Darryl C. Zeldin, Lawrence A. Tabak, Kelly G. Ten Hagen · 2021 · Proceedings of the National Academy of Sciences
  50. The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2
    Helena Winstone, María José Lista, Alisha C. Reid, Clément R. Bouton, Suzanne Pickering, Rui Pedro Galão, Claire Kerridge, Katie J. Doores, Chad M. Swanson, Stuart J. D. Neil · 2021 · Journal of Virology
  51. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types
    Zharko Daniloski, Tristan X. Jordan, Juliana K. Ilmain, Xinyi Guo, Gira Bhabha, Benjamin Robert tenOever, Neville E. Sanjana · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  52. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy
    Mina K. Chung, Sadashiva S. Karnik, Joshua Saef, Cornelia C. Bergmann, John Barnard, Michael M. Lederman, John C. Tilton, Feixiong Cheng, Clifford V. Harding, James B. Young et al. · 2020 · EBioMedicine
  53. Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection
    Scott B. Biering, Sylvia A. Sarnik, Eleanor Wang, James R. Zengel, Sarah R. Leist, Alexandra Schäfer, Varun Sathyan, Padraig Hawkins, Kenichi Okuda, Cyrus Tau et al. · 2022 · Nature Genetics
  54. Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential Role of Proteases beyond Furin
    Tiffany Tang, Javier A. Jaimes, Miya K. Bidon, Marco R. Straus, Susan Daniel, Gary R. Whittaker · 2021 · ACS Infectious Diseases
  55. PEDV: Insights and Advances into Types, Function, Structure, and Receptor Recognition
    Feng Lin, Huanyu Zhang, Linquan Li, Yang Yang, Xiaodong Zou, Jiahuan Chen, Xiaochun Tang · 2022 · Viruses
  56. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches
    Deep Bhowmik, Rajat Nandi, Rahul Jagadeesan, Niranjan Kumar, Amresh Prakash, Diwakar Kumar · 2020 · Infection Genetics and Evolution
  57. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges
    Anup Singh Pathania, Philip Prathipati, Bakrudeen AA. Abdul, Srinivas Prabhu Chava, Santharam S. Katta, Subash Chandra Gupta, Pandu R. Gangula, Manoj Kumar Pandey, Donald L. Durden, Siddappa N. Byrareddy et al. · 2020 · Theranostics
  58. Phosphatidylserine receptors enhance SARS-CoV-2 infection
    Dana Bohan, Hanora A. Van Ert, Natalie Ruggio, Kai J. Rogers, Mohammad Badreddine, José A. Aguilar-Briseño, Jonah M. Elliff, Roberth Anthony Rojas Chávez, Boning Gao, Tomasz Stokowy et al. · 2021 · PLoS Pathogens
  59. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes
    Yijia Li, Alexis M. Schneider, Arnav Mehta, Moshe Sade-Feldman, Kyle R. Kays, Matteo Gentili, Nicole C. Charland, Anna L. K. Gonye, Irena Gushterova, Hargun K. Khanna et al. · 2021 · Journal of Clinical Investigation
  60. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators
    Eirini Gkogkou, Grigoris Barnasas, Konstantinos N. Vougas, Ioannis P. Trougakos · 2020 · Redox Biology
  61. S-acylation controls SARS-CoV-2 membrane lipid organization and enhances infectivity
    Francisco Sarmento Mesquita, Laurence Abrami, Oksana A. Sergeeva, Priscilla Turelli, Enya Qing, Béatrice Kunz, Charlène Raclot, Jonathan Paz Montoya, Luciano A. Abriata, Tom Gallagher et al. · 2021 · Developmental Cell
  62. SARS-CoV-2 spike engagement of ACE2 primes S2′ site cleavage and fusion initiation
    Shi Yu, Xu Zheng, Bingjie Zhou, Juan Li, Mengdan Chen, Rong Xin Deng, Gary Wong, Dimitri Lavillette, Guangxun Meng · 2021 · Proceedings of the National Academy of Sciences
  63. The SARS-CoV-2 and other human coronavirus spike proteins are fine-tuned towards temperature and proteases of the human airways
    Manon Laporte, Valerie Raeymaekers, Ria Van Berwaer, Julie Vandeput, Isabel Marchand-Casas, Hendrik Jan Thibaut, Dominique Van Looveren, Katleen Martens, Markus Hoffmann, Piet Maes et al. · 2021 · PLoS Pathogens
  64. ADAM10 and ADAM17 promote SARS‐CoV‐2 cell entry and spike protein‐mediated lung cell fusion
    Georg Jocher, Vincent Grass, Sarah K. Tschirner, Lydia Riepler, Stephan Breimann, Tuğberk Kaya, Madlen Oelsner, M Sabri Hamad, Laura I. Hofmann, Carl Blobel et al. · 2022 · EMBO Reports
  65. A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes
    Tal Noy-Porat, Efi Makdasi, Ron Alcalay, Adva Mechaly, Yinon Levy, Adi Bercovich-Kinori, Ayelet Zauberman, Hadas Tamir, Yfat Yahalom-Ronen, Ma’ayan Israeli et al. · 2020 · Nature Communications
  66. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants
    Anshumali Mittal, Arun Khattri, Vikash Verma · 2022 · PLoS Pathogens
  67. SARS-CoV-2: Evolution and Emergence of New Viral Variants
    Verónica Roxana Flores-Vega, Jessica Viridiana Monroy-Molina, Luis Enrique Jiménez-Hernández, Alfredo G. Torres, José Ignacio Santos, Roberto Rosales-Reyes · 2022 · Viruses
  68. The role of cell surface sialic acids for SARS-CoV-2 infection
    Xue‐Long Sun · 2021 · Glycobiology
  69. The ocular surface, coronaviruses and COVID‐19
    Mark D. P. Willcox, Karen Walsh, Jason J. Nichols, Philip B. Morgan, Lyndon Jones · 2020 · Clinical and Experimental Optometry
  70. The genetic structure of SARS‐CoV‐2 does not rule out a laboratory origin
    Rossana Segreto, Yuri Deigin · 2020 · BioEssays
  71. Comparison of Four SARS-CoV-2 Neutralization Assays
    Riepler, Lydia, Rössler, Annika, Falch, Albert, Volland, André, Borena, Wegene, von Laer, Dorothee, Kimpel, Janine · 2020 · Vaccines
  72. Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
    Angel Yun-Kuan Thye, Jodi Woan‐Fei Law, Priyia Pusparajah, Vengadesh Letchumanan, Kok‐Gan Chan, Learn−Han Lee · 2021 · Biomedicines
  73. Small molecules in the treatment of COVID-19
    Sibei Lei, Xiaohua Chen, Jieping Wu, Xingmei Duan, Ke Men · 2022 · Signal Transduction and Targeted Therapy
  74. Pathogenesis, Clinical Manifestations and Complications of COVID-19
    Elaheh Kordzadeh-Kermani, Hossein Khalili, Iman Karimzadeh · 2020 · Future Microbiology
  75. Potential zoonotic sources of SARS‐CoV‐2 infections
    Wendy Karen Jo, Edmilson Ferreira de Oliveira-Filho, Andrea Rasche, Alex David Greenwood, Nikolaus Osterrieder, Jan Felix Drexler · 2020 · Transboundary and Emerging Diseases
  76. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
    Javier Tadeo Granados-Riveron, Guillermo Aquino‐Jarquín · 2021 · Biomedicine & Pharmacotherapy
  77. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
    Berislav Bošnjak, Saskia Catherina Stein, Stefanie Willenzon, Anne K. Cordes, Wolfram Puppe, Günter Bernhardt, Inga Ravens, Christiane Ritter, Christian R Schultze-Florey, Nina Gödecke et al. · 2020 · Cellular and Molecular Immunology
  78. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage
    Sandra Amor, Laura Fernández Blanco, David Baker · 2020 · Clinical & Experimental Immunology
  79. The choroid plexus and its role in the pathogenesis of neurological infections
    Derick Thompson, Catherine Ayn Brissette, John A. Watt · 2022 · Fluids and Barriers of the CNS
  80. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites
    Baofu Qiao, Mónica Olvera de la Cruz · 2020 · ACS Nano
  81. SARS-CoV-2 spike protein–induced cell fusion activates the cGAS-STING pathway and the interferon response
    Xiaoman Liu, Wei Ping Liang, Fengwen Xu, Fei Zhao, Yu Huang, Zhangling Fan, Shan Mei, Yamei Hu, Linxuan Zhai, Justin Guo et al. · 2022 · Science Signaling
  82. Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677
    Emma B. Hodcroft, Daryl Domman, Daniel J. Snyder, Kasopefoluwa Y. Oguntuyo, Maarten Van Diest, Kenneth H. Densmore, Kurt C. Schwalm, Jon Femling, Jennifer L. Carroll, Rona S. Scott et al. · 2021 · medRxiv
  83. Targeting Proteases for Treating COVID-19
    Binquan Luan, Tien Huynh, Xuemei M. Cheng, Ganhui Lan, Haoran Wang · 2020 · Journal of Proteome Research
  84. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation
    Bojan F. Hörnich, Anna K. Großkopf, Sarah Schlagowski, Matthias Tenbusch, Hannah Kleine‐Weber, Frank Neipel, Christiane Stahl‐Hennig, Alexander S. Hahn · 2021 · Journal of Virology
  85. Efficacy of Phytochemicals Derived from Avicennia officinalis for the Management of COVID-19: A Combined In Silico and Biochemical Study
    Shafi Mahmud, Gobindo Kumar Paul, Mirola Afroze, Shirmin Islam, Swagota Briti Ray Gupta, Mamudul Hasan Razu, Suvro Biswas, Shahriar Zaman, Md. Salah Uddin, Mala Khan et al. · 2021 · Molecules
  86. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines
    Wagner Gouvêa dos Santos · 2021 · Biomedicine & Pharmacotherapy
  87. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?
    Manoj Kumar Singh, Ahmed Mobeen, Amit Chandra, Sweta S. Joshi, Srinivasan Ramachandran · 2021 · Computers in Biology and Medicine
  88. Dependence of SARS-CoV-2 infection on cholesterol-rich lipid raft and endosomal acidification
    Xiaowei Li, Wenhua Zhu, Meiyang Fan, Jing Zhang, Yizhao Peng, Fumeng Huang, Nan Wang, Langchong He, Lei Zhang, Rikard Holmdahl et al. · 2021 · Computational and Structural Biotechnology Journal
  89. SARS-CoV-2 Antiviral Therapy
    Kaiming Tao, Philip L. Tzou, Janin Nouhin, Hector Fabio Bonilla, Prasanna Jagannathan, Robert W. Shafer · 2021 · Clinical Microbiology Reviews
  90. Targeting Androgen Regulation of TMPRSS2 and ACE2 as a Therapeutic Strategy to Combat COVID-19
    Qu Deng, Reyaz ur Rasool, Ronnie M. Russell, Ramakrishnan Natesan, Irfan Ahmed Asangani · 2020 · iScience
  91. Animal models for COVID-19: advances, gaps and perspectives
    Changfa Fan, Yong Wu, Rui Xiong, Yuansong Yang, Chen Ling, Susu Liu, Shunan Liu, Youchun Wang · 2022 · Signal Transduction and Targeted Therapy
  92. COVID-19 and diabetes mellitus: how one pandemic worsens the other
    William S. Azar, Rachel Njeim, Angie H Fares, Nadim S. Azar, Sami T. Azar, Mazen J. El Sayed, Assaad Antoine Eid · 2020 · Reviews in Endocrine and Metabolic Disorders
  93. Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda
    Daniel Lule Bugembe, My V. T. Phan, Isaac Ssewanyana, Patrick Semanda, Hellen Nansumba, Beatrice Dhaala, Susan Ndidde Nabadda, Aine Niamh O’Toole, Andrew Rambaut, Pontiano Kaleebu et al. · 2021 · Nature Microbiology
  94. The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea
    Mi Kyung Kim, Jae‐Han Jeon, Sung-Woo Kim, Jun Sung Moon, Nan Hee Cho, Eugene Han, Ji Hong You, Ji Yeon Lee, Miri Hyun, Jae Seok Park et al. · 2020 · Diabetes & Metabolism Journal
  95. Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions
    Mushtaq Hussain, Nusrat Jabeen, Anusha Amanullah, Ayesha Ashraf Baig, Basma Aziz, Sanya Shabbir, Fozia Raza, Nasir Uddin · 2020 · AIMS Microbiology
  96. ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
    Federica Saponaro, Grazia Rutigliano, Simona Sestito, Lavinia Bandini, Barbara Storti, Ranieri Bizzarri, Riccardo Zucchi · 2020 · Frontiers in Molecular Biosciences
  97. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
    Joseph J. Sabatino, Kristen Mittl, William M. Rowles, Kira McPolin, Jayant V. Rajan, Matthew T. Laurie, Colin R. Zamecnik, Ravi Dandekar, Bonny D. Alvarenga, Rita P. Loudermilk et al. · 2022 · JCI Insight
  98. SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping
    Gagandeep Kaur, Giuseppe Lungarella, Irfan Rahman · 2020 · Journal of Inflammation
  99. Gene of the month: TMPRSS2 (transmembrane serine protease 2)
    Michelle C. Thunders, Brett Delahunt · 2020 · Journal of Clinical Pathology
  100. Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study
    Dennis Freuer, Jakob Linseisen, Christa Meisinger · 2021 · Metabolism